Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer

Wu, Huan; Li, Rongrong; Zhang, Zhiwei; Jiang, Hai; Ma, Hongbing; Yuan, Cunzhong; Sun, Ce; Li, Yingwei; Kong, Beihua

doi:10.1186/s13048-019-0601-6

Cited by 16 publications

(12 citation statements)

References 28 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, BCL7A expression was negatively correlated with glioma grades. These results strongly suggest that BCL7A is a potential novel tumor suppressor gene in glioma, similar findings were reported previously [ 26 ]. We also investigated the prognostic role of BCL7A for the first time in glioma.…”

Section: Discussionsupporting

confidence: 92%

“…Elsewhere, ovarian cancer (OC) patients with high expression of BCL7A had shorter overall survival (OS) /progression-free survival (PFS) than those with low levels of BCL7A. BCL7A expression was implicated as an independent risk factor for poor prognosis OC patients [ 26 ]. Consistent with the role of BCL7A in OC, we identified BCL7A as a novel prognostic biomarker for LGG patients and GBM patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

BCL7A as a novel prognostic biomarker for glioma patients

Liu

Gao

et al. 2021

J Transl Med

View full text Add to dashboard Cite

Background Glioma is the most common primary brain tumor and represents one of the most aggressive and lethal types of human cancer. BCL7 family has been found in several cancer types and could be involved in tumor progression. While the role of BCL7 family in human glioma has remained to be elucidated. Methods Paraffin-embedded tumor samples were obtained to detect BCL7 expression by performing in glioma. Data (including normalized gene expression and corresponding clinical data) were obtained from Gliovis, CGGA, GEO, cBioportal and Oncomine and were used to investigate BCL7 genes expression in glioma. Survival analyses were calculated by Kaplan–Meier methods and Cox regression analysis in TCGA and CGGA. Gene Set Enrichment Analyses (GSEA) and gene ontology (GO) analysis was employed to perform the biological processes enrichment. Results BCL7A expression in glioma tissues was lower compared to non-tumor brain tissues (NBT), and exhibited a negative correlation with glioma grades. Results from immunohistochemical (IHC) staining and public dataset validation demonstrated that BCL7B and BCL7C were highly expressed in glioma tissues compared to NBT. Cox regression analysis identified BCL7A as the only gene in the BCL7 family that was independently associated with the prognosis of lower-grade glioma (LGG) and glioblastoma (GBM). GO and GSEA analyses revealed the potential contribution of BCL7A in adaptive immune response and neutrophil activation in the tumor microenvironment. Moreover, we found that BCL7A had no prognostic effect on the overall survival of GBM patients who received IR only; however, patients who received chemotherapy (TMZ) combined with IR in the high BCL7A group survived longer than patients in the low BCL7A group (HR = 0.346, p < 0.05). Conclusion BCL7A is a new tumor suppressor gene and can be adopted as a biomarker for independent prognosis in glioma and to evaluate response to TMZ.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

BCL7A as a novel prognostic biomarker for glioma patients

Liu

Gao

et al. 2021

J Transl Med

View full text Add to dashboard Cite

show abstract

“…Test classification was also shown to be associated with expression of complement C2, complement factor B, RBP4, kallistatin, C9, CRP, insulin-like growth factor-binding protein 1 (IGF-1), and D-dimer. Association of these proteins with prognosis in cancer, in general, and EOC, in particular, has been observed in previous studies [37][38][39][40][41][42][43]. In this regard, meta-analyses demonstrated that high CRP levels were associated with increased risk of invasive EOC [38], whereas no significant association of IGF-1/IGFBP-3 with EOC risk was identified [39].…”

Section: Discussionmentioning

confidence: 58%

“…In this regard, meta-analyses demonstrated that high CRP levels were associated with increased risk of invasive EOC [38], whereas no significant association of IGF-1/IGFBP-3 with EOC risk was identified [39]. In addition, RBP4 was shown to drive ovarian cancer cell migration [40]; pretreatment plasma D-dimer levels were associated with chemoresistance and poor disease outcome [41,42]; and low expression of kallistatin was associated with unfavorable prognosis, platinum resistance, and relapse [43]. These results indicate a potential relation to the individual immunological host-response to cancer.…”

Section: Discussionmentioning

confidence: 99%

Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer

Kasimir‐Bauer

Roder

Obermayr

et al. 2020

Cancers

View full text Add to dashboard Cite

Mass-spectrometry-based analyses have identified a variety of candidate protein biomarkers that might be crucial for epithelial ovarian cancer (EOC) development and therapy response. Comprehensive validation studies of the biological and clinical implications of proteomics are needed to advance them toward clinical use. Using the Deep MALDI method of mass spectrometry, we developed and independently validated (development cohort: n = 199, validation cohort: n = 135) a blood-based proteomic classifier, stratifying EOC patients into good and poor survival groups. We also determined an age dependency of the prognostic performance of this classifier, and our protein set enrichment analysis showed that the good and poor proteomic phenotypes were associated with, respectively, lower and higher levels of complement activation, inflammatory response, and acute phase reactants. This work highlights that, just like molecular markers of the tumor itself, the systemic condition of a patient (partly reflected in proteomic patterns) also influences survival and therapy response in a subset of ovarian cancer patients and could therefore be integrated into future processes of therapy planning.

show abstract

“…Therefore, further to elucidate the chemotherapy resistance mechanism of HGSOC is of great signi cance to reduce chemotherapy resistance and improve the prognosis of HGSOC patients. Our group has focused on chemo-resistance of ovarian cancer for many years [3][4][5]. Recent years, the role of tumor microenvironment in chemoresistance of ovarian cancer has aroused our interest.…”

Section: Introductionmentioning

confidence: 99%

Asporin Is Highly Expressed in CAFs of High Grade Serous Ovarian Cancinoma Patients and Predicts Poor Prognosis

Wang

Zheng

Zhang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Tumor microenvironment is widely considered as a critical factor influencing prognosis of ovarian cancer patients. To further improve the unsatisfied clinical outcome of ovarian cancer patients, it is desperately needed to explore biomarkers with potential clinical value of ovarian cancer. Asporin (ASPN), as a member of the proteoglycan family in tumor microenvironment, has been proved to play a vital role in cancer progression by binding with CD44 receptor. However, there is still no report about the research of Asporin in ovarian cancer. The purpose of the present study was to explore the expression and prognostic significance of Asporin in high grade serous ovarian cancinoma(HGSOC). Methods: The expression level of Asporin and CD44 in 85 formalin fixed paraffin embedded (FFPE) samples of 85 HGSOC patients was detected by immunohistochemistry. The association between the expression of the two biomarkers and the clinicopathologic factors of HGSOC was assessed by χ² test. The survival analyses were performed by Kaplan-Meier.Results: Asporin was mainly expressed in CAFs of 85 HGSOC patients, while CD44 was mainly expressed on membrane of tumor cells. The positive rates of Asporin, CD44, and Asporin /CD44 co-expression were 43.53% (37/85), 34.12% (29/85) and 28.23% (24/85) in 85 HGSOC tissues, respectively. There were close associations between Asporin, CD44, Asporin/CD44 expression and CA125 level of blood, tumor differentiation, FIGO staging, chemoresistance of HGSOC patients. Further, univariate survival analysis showed that positive expression of Asporin and positive Asporin/CD44 co-expression of HGSOC indicated poor clinical outcomes, and multivariate survival analysis suggested that positive expression of Asporin and positive Asporin/CD44 co-expression were independent prognostic factors for disease–free survival (DFS) and overall survival (OS) of HGSOC patients, respectively.Conclusion: Asporin was mainly expressed in CAFs of HGSOC patients. High expression of Asporin may identify a subgroup of HGSOC patients with more chemoresistance clinicopathological features and may be a potential prognostic predictor and therapeutic target for HGSOC patients.

show abstract

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer

Cited by 16 publications

References 28 publications

BCL7A as a novel prognostic biomarker for glioma patients

BCL7A as a novel prognostic biomarker for glioma patients

Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer

Asporin Is Highly Expressed in CAFs of High Grade Serous Ovarian Cancinoma Patients and Predicts Poor Prognosis

Contact Info

Product

Resources

About